GlassScriptPhysician profile
James O Theis
NPI 1780773440
$3,741.64
in general payments reported to CMS, 2019-2025
29 companies · $509 in 2025
The $509 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $693 · 2020: $620 · 2021: $588 · 2022: $314 · 2023: $393 · 2024: $624 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,526.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $682.17 | 2019-2025 | Ozempic, Wegovy, Saxenda |
| Amgen INC. | $618.87 | 2019-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $458.18 | 2020-2025 | Farxiga, Breztri |
| Abbvie INC. | $417.33 | 2019-2025 | Ubrelvy, Qulipta |
| Lilly USA, LLC | $268.96 | 2019-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $260.51 | 2019-2025 | Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.17 | 2019-2025 | Jardiance |
| Pfizer INC. | $159.02 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $77.31 | 2019-2021 | |
| Astellas Pharma US INC | $62.79 | 2019-2021 | |
| Glaxosmithkline, LLC. | $61.06 | 2022-2025 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $57.92 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Esperion Therapeutics, INC. | $53.96 | 2020-2021 | |
| Allergan, INC. | $49.25 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $43.75 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.10 | 2019-2023 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $33.99 | 2019-2020 | |
| Inspire Medical Systems, INC. | $31.81 | 2025 | Inspire |
| Jazz Pharmaceuticals INC. | $26.05 | 2022 | |
| Exact Sciences Corporation | $23.54 | 2023 | Cologuard Collection Kit |
| Dexcom, INC. | $23.46 | 2023 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $20.19 | 2022 | |
| Gilead Sciences, INC. | $19.75 | 2025 | |
| Eisai INC. | $17.34 | 2020 | |
| Sanofi Pasteur INC. | $13.72 | 2020 | |
| Circassia INC. | $13.54 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.55 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.30 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Theis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.